HORMAD1 and lung adenocarcinoma: In contrast, two distinct studies demonstrated that HORMAD1 promotes HR in models of lung adenocarcinomas, providing a selective survival advantage for cancer cells (Gao et al., 2018; Nichols et al., 2018).